On December 13, 2018, Janssen Pharmaceuticals, Inc. announced it entered a results-based contract for its long-acting injectable antipsychotics (LAIs) with the Oklahoma Health Care Authority (OHCA), which manages Oklahoma's Medicaid plan, SoonerCare. The arrangement is focused on helping adults with schizophrenia to use the LAIs INVEGA SUSTENNA® (paliperidone palmitate) and INVEGA TRINZA® (paliperidone palmitate) earlier in treatment. The results-based contract is based on agreed-upon utilization measures over a six-month period compared to a baseline period.
INVEGA SUSTENNA is a monthly LAI for the treatment of adults with schizophrenia. INVEGA TRINZA is administered four times . . .